# Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Source: https://onco.cc/trials/nct05060276/  
OnCo record `nct05060276` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is withdrawn.

## Summary

The registry lists NCT05060276 as withdrawn, last updated 2023-01-26. Enrolment is 0 actual participants. Interventions: STI-3258. Primary measures include Incidence of adverse events by type, frequency, severity, and causality (safety); Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety). The registry reason for stopping is: Protocol changed to Phase 2 No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT05060276
- Phase: 1
- Setting: A Phase 1B, Dose-Escalation Study of the Safety and Preliminary Efficacy of an Anti-Trop2 Antibody Drug Conjugate (STI-3258) in Patients With Relapsed or Refractory Solid Tumors
- Sponsor: Sorrento Therapeutics, Inc.
- Enrolled: 0

## Sources

- ClinicalTrials.gov NCT05060276: https://clinicaltrials.gov/study/NCT05060276

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [STI-3258](https://onco.cc/drugs/sti-3258/)

---
JSON: https://onco.cc/api/v1/entities/nct05060276.json